# A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease

> **NCT03922711** · PHASE2 · TERMINATED · sponsor: **Prilenia** · enrollment: 23 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Pridopidine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03922711
- **Lead sponsor:** Prilenia
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-22
- **Primary completion:** 2020-07-22
- **Final completion:** 2020-07-22
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** COVID-19
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03922711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03922711, "A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03922711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*